Search

Your search keyword '"Spornraft‐Ragaller, Petra"' showing total 172 results

Search Constraints

Start Over You searched for: Author "Spornraft‐Ragaller, Petra" Remove constraint Author: "Spornraft‐Ragaller, Petra"
172 results on '"Spornraft‐Ragaller, Petra"'

Search Results

1. Gonorrhoe bei Erwachsenen und Adoleszenten

6. Stellungnahme der Deutschen STI‐Gesellschaft zur antibiotischen STI‐Prophylaxe mit Doxycyclin (Doxy‐PEP, Doxy‐PrEP): Position Statement of the German STI Society on the Prophylactic Use of Doxycycline to Prevent STIs (Doxy‐PEP, Doxy‐PrEP)

7. Position statement of the German STI Society on the prophylactic use of doxycycline to prevent STIs (Doxy‐PEP, Doxy‐PrEP).

12. A highly virulent variant of HIV-1 circulating in the Netherlands

19. Switching to a NRTI-free 2 drug regimen (2DR) –a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes.

35. Infektiöse Reisedermatosen

36. Travel‐associated infectious skin diseases

39. Chromated metal products may be hazardous to patients with chromate allergy

40. Additional file 2 of STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany

41. Additional file 1 of STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany

42. Additional file 3 of STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany

43. Travel-associated infectious skin diseases

44. Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study

45. S3 Guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 2

46. S3‐Leitlinie: Durchführung des Epikutantests mit Kontaktallergenen und Arzneimitteln – Kurzfassung Teil 2

47. S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

48. S3‐Leitlinie: Durchführung des Epikutantests mit Kontaktallergenen und Arzneimitteln – Kurzfassung Teil 1

50. Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study.

Catalog

Books, media, physical & digital resources